The Path Towards a Tailored Clinical Biosimilar Development

Since the first approval of a biosimilar medicinal product in 2006, scientific understanding of the features and development of biosimilar medicines has accumulated. This review scrutinizes public information on development programs and the contribution of the clinical studies for biosimilar approva...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiestl, Martin, Ranganna, Gopinath, Watson, Keith, Jung, Byoungin, Roth, Karsten, Capsius, Björn, Trieb, Michael, Bias, Peter, Maréchal-Jamil, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211192/
https://www.ncbi.nlm.nih.gov/pubmed/32266678
http://dx.doi.org/10.1007/s40259-020-00422-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211192/
https://www.ncbi.nlm.nih.gov/pubmed/32266678
http://dx.doi.org/10.1007/s40259-020-00422-1

Ejemplares similares